

Project Summary Information

	Date of Document Preparation: May 30, 2022			
Project Name	Côte d'Ivoire: Strengthening of Vaccination and Health Systems under the COVID-19 Strategic Preparedness and			
	Response Project			
Project Number	000560			
AIIB member	Republic of Côte d'Ivoire			
Sector/Subsector	Public Health/NA			
Status of Financing	Approved			
Project Description	The Project is financed under AIIB's COVID-19 Crisis Recovery Facility (the Facility) and is co-financed with the World Bank (WB), through the International Development Association (IDA), under the second additional financing of the Côte d'Ivoire Strategic Preparedness and Response Project (CIV-SPRP). The Project will: (i) increase the availability and roll-out of eligible vaccines for coronavirus disease 2019 (COVID-19), to support the Government of Côte d'Ivoire in its target to expand COVID-19 vaccination coverage to 70 percent of the population and provide booster doses to 9.9 million persons (35 percent of the population); (ii) reinforce preparedness and response interventions at scale; and (iii) strengthen relevant health systems to ensure effective vaccine deployment in Côte d'Ivoire, sustained containment of COVID-19, and positioning of the country to detect and respond to future disease outbreaks in a swift, effective and efficient manner.			
	The Project will comprise 3 components:			
	 Component 1: Emergency COVID-19 Response to finance the purchase and deployment of vaccines and to strengthen related health systems Component 2: Health communication and community engagement Component 3: Project implementation, management, and monitoring and evaluation 			
	AIIB will finance all three components.			
	The WB's earlier support to the CIV-SPRP consists of an initial IDA credit of USD 35 million (referred to as the Initial WB Financing), focused on initial measures to contain the pandemic, and an Additional WB Financing (AF) IDA credit of USD 100 million (referred to as the First WB AF), focused on vaccine deployment. Activities under all three components have been underway since Apr. 2021, within the framework of the CIV-SPRP. The Project will scale up activities under all three components and extend the closing date of the project from Jun. 30, 2022 to Jun. 30, 2024.			

Objective	To prevent, detect and respond to the threat posed by COVID-19 and strengthen national systems for public health			
	preparedness in Côte d'Ivoire.			
Expected Results	The Project results will include:			
	Number of COVID-19 tests conducted in females			
	2) Number of COVID-19 tests conducted in males			
	3) Percentage of positive COVID-19 cases in females			
	4) Percentage of positive COVID-19 cases in males			
	5) Percentage of the female population vaccinated, based on the targets defined in the National Deployment and Vaccination Plan for COVID-19 vaccines (NDVP)			
	6) Percentage of the male population vaccinated, based on the targets defined in the NDVP			
	7) Percentage of population covered by the communication, consultation, social and community mobilization interventions			
	8) Percentage of regional health poles that have an operational Emergency Operations Centre (EOC).			
Environmental and	World Book Catagory: Substantial Biok (equivalent to Catagory B if AllB's ESB were applicable)			
Social Category	World Bank Category: Substantial Risk (equivalent to Category B if AIIB's ESP were applicable)			
Environmental and	The loan will be co-financed with the WB as lead co-financier, and the project's environmental and social (ES) risks and			
Social Information	impacts will be assessed in accordance with the WB's Environmental and Social Framework (ESF). To ensure a harmonized			
	approach to addressing the ES risks and impacts of the project, and as permitted under AIIB's Environmental and Soci			
	Policy (ESP), the WB's ESF will apply to the project in lieu of AIIB's Environmental and Social Policy (ESP). AIIB h			
	reviewed the WB ESF and is satisfied that: (a) it is consistent with AIIB's Articles of Agreement and materially consistent			
	with the provisions of AIIB's ESP, including the Environmental and Social Exclusion List and the relevant Environmental an			
	Social Standards; and (b) the monitoring procedures that are in place are appropriate for the project.			
	The WB has categorized the environmental and social (ES) risks of the project as "Substantial" (which is equivalent to			
	Category B if AIIB's ESP were applicable). However, the Project is expected to have mostly positive ES impacts, insofar as			
	it should strengthen COVID-19 surveillance, monitoring, treatment, containment and response in accordance with World			
	Health Organization (WHO) guidelines and prepare the country for future pandemics. The main environmental risks result			
	from inherent occupational and community health and safety risks and the challenges associated with medical waste			
	management. The main social risks relate to difficulties of access, or lack of access to, health supplies, services and facilities			
	by vulnerable social groups, lack of public acceptance and mistrust of vaccines, social conflicts and risks to human safety			
	related to diagnostic testing, and social tensions related to the challenges of a pandemic situation. Social risks will be			

mitigated through effective risk communication and community engagement to raise awareness among the general population.

Regarding Grievance Redress Mechanisms (GRM), this comprises of a telephone hotline established at the Ministry of Health, email address channels, social media channels, and complaints-handling desks at the health care facilities, clinics and hospitals. The GRM will handle all Project-related concerns on the process of managing the pandemic and the medical waste management activities, including: (i) the search and management of COVID-19 cases; (ii) the treatment of the sick; (iii) psychological assistance; (iv) issues regarding vaccine deployment and implementation; and (v) other issues such as death cases.

The relevant ES documentation has been disclosed on WB's website (https://projects.worldbank.org/en/projects-operations/project-detail/P176257) and on the client's website (https://sante.gouv.ci/welcome/publications_liste).

Cost and Financing Plan

The total Project cost is approximately USD 180 million, with co-financing by AIIB and WB/IDA.

Modality and Sources	Amount (million USD equivalent)
World Bank**	
IDA Credit	80.0
AIIB	
COVID-19 Crisis Recovery Facility	100.0
Total	180.0

** World Bank's total combined financing under the Initial WB Financing, First WB AF, and this Project is USD 215 million, as follows:

World Bank Financings	Amount (million USD equivalent)	
Initial WB Financing (IDA Credit)	35.0	
First AF (IDA Credit)	100.0	
Proposed Project (IDA Credit)	80.0	
Total WB Financing	215.0	

Borrower

Republic of Côte d'Ivoire

Implementing	Ministry of Health and Public Hygiene (Ministere de la Sante et de l'Hygiene Publique (MSHP)), World Bank Health				
Entity	Projects' Coordination Unit (l'Unité de Coordination des Projets Santé de la Banque Mondiale (UCP-BM))				
Estimated date of					
loan closing	November 30, 2024				
Contact Points:	AIIB	WB	Implementing entity		
Name	Suzanne Shaw	Opope Oyaka Tshivuila Matala	Clovis Konan		
Title	Infrastructure Sector Economist	Senior Health Specialist	Coordinator of World Bank Health Projects'		
			Coordination Unit, Ministry of Health and Public		
			Hygiene		
Email Address	suzanne.shaw@aiib.org	otshivuilamatala@worldbank.org	clovisko@yahoo.fr		
Date of Concept	December 9, 2004				
Decision	December 8, 2021				
Date of Appraisal	December 8, 2021				
Decision					
Date of Financing	May 25, 2022				
Approval					

Independent
Accountability
Mechanism

The WB's ESF will apply to this Project instead of AIIB's ESP. The WB's corporate Grievance Redress Service (GRS) and its Independent Accountability Mechanism (IAM), the Inspection Panel, which reviews the WB's compliance with its policies and procedures, will handle complaints relating to the WB's compliance with its ESF with respect to the Project. In accordance with AIIB's Policy on the Project affected People's Mechanism (PPM), submissions to the PPM regarding such complaints under this Project will not be eligible for consideration by the PPM. Information on WB's corporate GRS is available at http://www.worldbank.org/en/projects-operations/products-and-services/grievance-redress-service. Information on WB's Inspection Panel is available at http://www.inspectionpanel.org.